Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Escitalopram.

William J Burke1

  • 1University of Nebraska Department of Psychiatry, 985580 Nebraska Medical Center, Omaha, NE 68198-5580, USA. wjburke@unmc.edu

Expert Opinion on Investigational Drugs
|October 22, 2002
PubMed
Summary
This summary is machine-generated.

Escitalopram oxalate, an antidepressant, effectively treats depression and anxiety disorders by selectively inhibiting serotonin reuptake. It demonstrates superior efficacy and a favorable safety profile compared to placebo.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human-Animal Chimera Formation for Organ Transplantation: Subjugating Human Embryonic Development to Animal Control.

The Linacre quarterly·2023
Same author

Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2).

International psychogeriatrics·2023
Same author

Sustainable intensification in jeopardy: Transdisciplinary evidence from Malawi.

The Science of the total environment·2022
Same author

Design and Development of a Community-Based, Interdisciplinary, Collaborative Dementia Care Program.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry·2021
Same author

Healthy People and Interested Students: Medical and Pharmacy Students' Knowledge and Attitudes Regarding Public Health.

Pharmacy (Basel, Switzerland)·2021
Same author

Health Outcomes Associated with Adherence to Antidepressant Use during Acute and Continuation Phases of Depression Treatment among Older Adults with Dementia and Major Depressive Disorder.

Journal of clinical medicine·2020
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Psychiatry
  • Clinical Trials

Background:

  • Escitalopram oxalate is the S-enantiomer of citalopram, a selective serotonin reuptuptake inhibitor (SSRI).
  • Preclinical data indicate therapeutic activity resides in the S-isomer, with high affinity for the serotonin transporter.
  • R-citalopram exhibits significantly lower potency at the serotonin transporter.

Purpose of the Study:

  • To evaluate the efficacy and safety of escitalopram oxalate in treating depression and anxiety disorders.
  • To compare the therapeutic activity of escitalopram with placebo and citalopram.
  • To assess the pharmacokinetic profile and potential for drug-drug interactions.

Main Methods:

  • Multiple short-term, placebo-controlled clinical trials were conducted.

Related Experiment Videos

  • Some trials included citalopram as an active control.
  • A 36-week study assessed depression relapse prevention.
  • Safety data from a comprehensive database were analyzed.

    • Main Results:

    • Escitalopram demonstrated robust efficacy in treating major depressive disorder and associated anxiety symptoms compared to placebo.
    • Efficacy was also observed in generalized anxiety disorder, panic disorder, and social anxiety disorder.
    • Escitalopram showed earlier statistically significant superiority over placebo than citalopram at comparable doses.
    • Low discontinuation rates due to adverse events were reported, with no significant difference from placebo.

    Conclusions:

    • Escitalopram oxalate is an effective SSRI for depression and various anxiety disorders.
    • The drug exhibits a favorable safety profile with a low incidence of adverse events.
    • Linear pharmacokinetics and minimal cytochrome P450 interactions suggest predictable dosing and reduced drug-drug interaction potential.